Xanthine oxidase inhibitor formulations

EP4568704A4Pending Publication Date: 2026-07-22XORTX THERAPEUTICS INC
View PDF 0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
EP · EP
Patent Type
Applications
Current Assignee / Owner
XORTX THERAPEUTICS INC
Filing Date
2023-08-08
Publication Date
2026-07-22

AI Technical Summary

Technical Problem

Xanthine oxidase inhibitors, such as allopurinol and oxypurinol, are poorly soluble and bioavailable, leading to inefficiencies in treating conditions like gout and hyperuricemia, with existing formulations experiencing side effects and limited bioavailability.

Method used

Development of novel formulations incorporating organic bases to enhance the solubility and bioavailability of xanthine oxidase inhibitors, including liquid compositions with specific ratios of xanthine oxidase inhibitors and organic bases like arginine or lysine, which increase solubility and reduce side effects.

Benefits of technology

The formulations demonstrate improved solubility, bioavailability, and reduced side effects, enabling more effective treatment of hyperuricemia-related conditions by increasing nitric oxide availability and decreasing oxygen free radical production.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 1.1
    Figure 1.1
Patent Text Reader

Abstract

Disclosed herein are methods and compositions for involving a xanthine oxidase inhibitor that has enhanced solubility. The compositions described herein include a xanthine oxidase inhibitor combined with an organic base. The compositions can be used to treat a disease or medical condition that involves elevated uric acid levels.
Need to check novelty before this filing date? Find Prior Art